Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Thyrocare TechnologiesNSE:THYROCARE -2.71%89 Return-on-Tangible-Asset is 32.85% as of Jun. 2026, which is 39% above its 10-year median of 23.58. GuruFocus rates NSE:THYROCARE with a GF Score™ of 89/100 and a GF Value™ of ₹425.05 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 212 Medical Diagnostics & Research companies, Thyrocare Technologies ranks better than 96.7% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Thyrocare Technologies's annualizedNet Income for the quarter that ended in Jun. 2026 was ₹2,088 Mil. Thyrocare Technologies's average total tangible assets for the quarter that ended in Jun. 2026 was ₹6,354 Mil. Therefore, Thyrocare Technologies's annualized Return-on-Tangible-Asset for the quarter that ended in Jun. 2026 was 32.85%.
The historical rank and industry rank for Thyrocare Technologies's Return-on-Tangible-Asset or its related term are showing as below:
NSE:THYROCARE'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 12.42 Med: 23.58 Max: 37.04
Current: 29.67
During the past 13 years, Thyrocare Technologies's highest Return-on-Tangible-Asset was 37.04%. The lowest was 12.42%. And the median was 23.58%.
NSE:THYROCARE's Return-on-Tangible-Asset is ranked better than 96.7% of 212
companies
in the Medical Diagnostics & Research industry
Industry Median: -2.02
vs NSE:THYROCARE: 29.67
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Thyrocare Technologies Return-on-Tangible-Asset Related Terms
Thyrocare Technologies Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Thyrocare Technologies's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:THYROCARE vs TMO, DHR, IDXX: Return-on-Tangible-Asset Comparison
For the Diagnostics & Research subindustry, Thyrocare Technologies's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Thyrocare Technologies Return-on-Tangible-Asset vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Thyrocare Technologies's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Thyrocare Technologies's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Jun. 2026) net income data.
What does a Return-on-Tangible-Asset of 32.85% mean?
Thyrocare Technologies (NSE:THYROCARE) has a Return-on-Tangible-Asset of 32.85% as of Jun. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Thyrocare Technologies and its competitors. This is 39% above median its historical median of 23.58. Over the past decade, Thyrocare Technologies' Return-on-Tangible-Asset has ranged from 12.42 to 37.04. According to the industry distribution chart, Thyrocare Technologies ranks #7 out of 212 companies in the Medical Diagnostics & Research industry, placing it in the top 3.3%.
Is Thyrocare Technologies' Return-on-Tangible-Asset too high?
Thyrocare Technologies' current Return-on-Tangible-Asset of 32.85% is 39% above median its 10-year median of 23.58. Over the past 10 years, this metric has ranged from a low of 12.42 to a high of 37.04. Based on the distribution chart, Thyrocare Technologies ranks #7 out of 212 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Thyrocare Technologies has a GF Score™ of 89/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Thyrocare Technologies' Return-on-Tangible-Asset compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Thyrocare Technologies ranks #7 out of 212 companies for Return-on-Tangible-Asset. This places Thyrocare Technologies in the top 3% of its industry — outperforming the majority of peers. Historically, Thyrocare Technologies' own Return-on-Tangible-Asset has ranged from 12.42 to 37.04 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Diagnostics & Research company?
A good Return-on-Tangible-Asset depends on the Medical Diagnostics & Research industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Thyrocare Technologies and its competitors. Thyrocare Technologies's current Return-on-Tangible-Asset is 32.85%, which is 39% above median its own 10-year median of 23.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Thyrocare Technologies stock overvalued right now?
Based on GuruFocus' analysis, Thyrocare Technologies (NSE:THYROCARE) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹425.05, compared to a current price of ₹566.70 — trading 33.3% above its estimated fair value. The current Return-on-Tangible-Asset is 32.85%, which is 39% above median its 10-year median of 23.58. Thyrocare Technologies' overall GF Score™ is 89/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Thyrocare Technologies (NSE:THYROCARE), the current Return-on-Tangible-Asset is 32.85% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Thyrocare Technologies (NSE:THYROCARE) Overvalued in 2026?
Based on GuruFocus' analysis, Thyrocare Technologies stock appears to be overvalued.
The current stock price of ₹566.70 is trading 33.3% above its estimated GF Value™ of ₹425.05.
GuruFocus considers Thyrocare Technologies to be Significantly Overvalued.
Key valuation signals for NSE:THYROCARE:
Return-on-Tangible-Asset: 32.85% (39% above median its 10-year median of 23.58)
GF Value™: ₹425.05 vs. price of ₹566.70 (33.3% above fair value)
No single metric tells the full story. See the NSE:THYROCARE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Thyrocare Technologies Ltd is a diagnostics & research company. The company has three business segments: Diagnostic Testing Services, Imaging Services, and Others: Sale of testing equipment and consumables. The Diagnostic Testing Services segment provides Diagnostic and testing services, selling of consumables used for the collection and promotion of the pathology segment. The company majorly earns the majority of its revenue from the Diagnostic Testing Services segment. The Imaging Services segment operates Diagnostic and imaging services, selling of radio-pharmaceuticals, and selling of consumables for reporting. The Other business segment is engaged in the selling of glucometers and glucostrips under the brand name Sugarscan. The company earns the vast majority of its revenue in India.
89GF Score
Get the complete analysis for NSE:THYROCARE
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:THYROCARE has been successfully added to your 
